drug
relugolix
Marketedupdated 3mo agoby Sumitomo Pharma America Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Prostate Cancer
all catalysts(4)
Trials studying relugolix
- —A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
- phase3The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
- phase2Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
- phase2A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
- phase2Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
- phase2Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
- phase1Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
- phase3REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 28, 2029
~2.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Sep 29, 2037method-of-use (U-3020)US 10449191
- Sep 29, 2037method-of-use (U-3020)US 10786501
- Sep 29, 2037method-of-use (U-3020)US 11583526
- Sep 29, 2037method-of-use (U-3020)US 12097198
- Sep 29, 2037method-of-use (U-4035)US 12144809
- Sep 29, 2037method-of-use (U-3020)US 12336990
- Feb 25, 2036formulationUS 10350170
- Sep 27, 2033compositionUS 11795178
- Sep 27, 2033compositionUS 12325714
- Jan 28, 2029compositionUS 73009352.4y
- Jan 28, 2026compositionUS 8058280
News(1)
- REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate CancerSagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.onclive · 3mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that